Management of Hormone-Refractory Advanced Prostate Cancer
The NCCN Guidelines are continuously updated to reflect the newest standards of care in oncology. With the increased pace of cancer research, the breadth of disease sites, the emergence of new diagnostic markers and imaging techniques, and the explosion of new treatment options clinicians are challenged to keep up with these advances. The new treatment options for prostate cancer include minimally invasive surgical procedures, new classes of cytotoxic agents, and novel biologically targeted agents. Therefore, there is a great need for clinicians to maintain and continually add to their knowledge of scientific concepts and how those concepts can be applied in the everyday practice setting. This program will focus on management of advanced disease.
This educational activity is designed to meet the needs of physicians, nurses, pharmacists, and other clinical professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Evaluate available clinical evidence for the management of hormone-refractory advanced prostate cancer
Philip W. Kantoff, MD
Dana-Farber/Brigham and Women's Cancer Center
- 0.25 Participation
- 0.29 Nurse
- 0.25 Pharmacist
- 0.25 Physician